Účinnost a bezpečnost podávání moxonidinu u pacientů s metabolickým syndromem (klinické hodnocení O.B.E.Z.I.T.A.)
Title in English | The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial) |
---|---|
Authors | |
Year of publication | 2011 |
Type | Article in Periodical |
Magazine / Source | Vnitřní lékařství |
MU Faculty or unit | |
Citation | |
Field | Endocrinology, diabetology, metabolism, nutrition |
Keywords | metabolic syndrome; uncontrolled hypertension; metabolically neutral products; obesity; clinical trial |
Description | Tratment with agents neutral to lipid metabolism but with a positive effect on glucose metabolism might significantly improve ther long-term prognosis of patients with metabolic syndrome and hypertension. The aim of our non-interventional observational clinical study was to evaluate the safety of treatment with moxonidine and to assess changes to the metabolic syndrome-related laboratory parameters. Over the 6-month follow up, a highly significant change was observed to all monitored parameters. An addition of monoxidine to an existing treatment resulted not only in a reduction to blood pressure but also in highly significant changes to metabolic parameters without any significant modifications of the treatment. Treatment with monoxidine can be considered as metabolically neutral with an added value of positive effect on metabolic parameters. This is a line with the results of other studies. |
Related projects: |